Antibody Discovery News and Research

RSS

Research finding could lead to first effective therapies, vaccines against dengue virus

Researchers at Vanderbilt University and the National University of Singapore have determined the structure of a human monoclonal antibody which, in an animal model, strongly neutralizes a type of the potentially lethal dengue virus.

3 Jul 2015

CRT, BioInvent, and University of Southampton partner to develop new immunotherapy treatments for cancer

Cancer Research Technology, the commercialization and development arm of Cancer Research UK and BioInvent International today announce the start of a two-year research collaboration with leading antibody researchers at the University of Southampton.

30 Mar 2015

New CRUK-MEDI Alliance Laboratory to focus on development of novel biologic cancer treatments

CANCER RESEARCH UK, with its commercial arm Cancer Research Technology, today announce that they have entered into an innovative collaboration with AstraZeneca and MedImmune, its global biologics research and development arm, to establish a joint laboratory in Cambridge, UK.

25 Sep 2014

A*STAR, Roche partner to identify novel drug targets for cancer treatment

A*STAR's Bioprocessing Technology Institute has entered into an agreement with one of the world's largest pharmaceutical company, Roche, to identify novel drug candidates for the detection and treatment of cancer.

15 Jul 2014

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, India (GPL), announced the opening of its new cGMP compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. T

4 Jun 2014

arGEN-X, Shire Pharmaceuticals announce long-term strategic alliance in therapeutic antibodies

arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a long-term strategic alliance with Shire Pharmaceuticals.

4 Jun 2014

arGEN-X collaborates with Bayer Pharma for development of therapeutic antibodies

arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today the initiation of a collaboration with Bayer Pharma AG (Bayer), leveraging arGEN-X's SIMPLE Antibody™ technology for the discovery and development of therapeutic antibodies.

28 May 2014

Integral Molecular announces new patent protecting use of lipoparticles for eliciting antibodies against protein targets

Integral Molecular, a leader in membrane protein antibody discovery, announces the issuance of a new patent protecting the use of Lipoparticles for eliciting antibodies against membrane protein targets.

29 Mar 2014

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc., an oncology-focused biopharmaceutical company.

13 Mar 2014

Domain Therapeutics, XOMA to jointly evaluate DTect-All to identify allosteric modulator antibodies

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces it has entered into a multi-step collaboration with XOMA Corporation, a leader in the discovery and development of therapeutic antibodies.

4 Feb 2014

MedImmune, Johns Hopkins University enter into $6.5M research collaboration

MedImmune, AstraZeneca’s global biologics research and development arm, and The Johns Hopkins University today announced they have entered into a five-year, $6.5 million research collaboration.

12 Dec 2013

BioInvent International receives US patent for drug discovery technology F.I.R.S.T.

BioInvent International AB today announces that it has been granted a US patent for its antibody and concomitant target discovery technology F.I.R.S.T.

11 Nov 2013

Heptares' StaR platform offers breakthrough solution to challenge associated with antibodies therapeutics

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, achieved the first research milestone in its antibody therapeutics alliance with MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX), announced in February 2013.

10 Oct 2013

arGEN-X and Shire achieve milestone in SIMPLE Antibody R&D collaboration

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.

19 Sep 2013

arGEN-X generates potent antibody antagonists of Nav1.7 using SIMPLE Antibody technology

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has successfully generated potent antibody antagonists of Nav1.7, using its proprietary SIMPLE Antibody™ technology.

12 Sep 2013

Adimab Scores Two Deals And Some Milestone Payments

...

22 Aug 2013

TSRI scientists find way to directly turn bone marrow stem cells into brain cells

In a serendipitous discovery, scientists at The Scripps Research Institute have found a way to turn bone marrow stem cells directly into brain cells.

23 Apr 2013

Integral Molecular releases MPS antibody discovery platform

ntegral Molecular, Inc., a leader in membrane protein reagents and services, announces the launch of its Membrane Protein Solutions antibody discovery platform.

23 Apr 2013

Third Rock Ventures announces formation of Jounce Therapeutics

Third Rock Ventures, LLC today announced the formation of Jounce Therapeutics, Inc. with a $47 million Series A financing of the company. Jounce is focused on the discovery and development of first-in-class cancer immunotherapies designed to harness the patient's immune system to seek out and attack cancerous cells and tumors.

15 Feb 2013

Dyax fourth quarter total revenues increase to $16.0 million

Dyax Corp. today announced financial results for the fourth quarter and year ended December 31, 2012.

14 Feb 2013